AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.9 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Design and Development of Valsartan-Loaded Solid Lipid Nanoparticles for the Enhanced Protection from Diabetic Neuropathy

Arun RadhakrishnanSenthil Venkatachalam( )Bhavani Paruchuri
Department of Pharmaceutics, JSS College of Pharmacy, Ooty, JSS Academy of Higher Education and Research, India
Show Author Information

Abstract

Valsartan has shown to be effective against diabetic neuropathy. In this study we designed, developed and characterized valsartan loaded solid lipid nanoparticles to enhance the protection against diabetic neuropathy. Nerve function parameters and behavioural studies were performed in male mice. Valsartan-loaded solid lipid nanoparticles (VSLNs) were formulated using palmitic acid as lipid and poloxamer188 as surfactant by solvent diffusion method. VSLNs were characterized for particle size and zeta potential analysis, morphology, drug entrapment efficiency and drug loading. In vitro drug release studies were performed in phosphate buffer of pH 7.4 by using dialysis bag method. In vivo studies such as motor nerve conduction velocity, thermal nociception and mechanical nociception studies were performed with both VSLNs and pure drug. The optimized batch was the one with 1:2 ratio of drug and lipid, and 1% surfactant was found to have the particle size of 457 nm, zeta potential of –16 mV, entrapment efficiency of 78.9±0.05%, drug loading of 26.22±0.05% and in vitro drug release of 84.84±0.07% over a period of 24 h. Based on these results, we concluded that VSLNs showed better protection from diabetic neuropathy.

References

[1]

C.J. Woolf, R. J Mannion, Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet, 1999, 353: 1959-1965.

[2]

R.H. Dworkin, An overview of neuropathic pain: syndromes, symptoms, signs and several mechanisms. The Clinical Journal of Pain, 2002, 18: 343-349.

[3]

L. Werhagen, C.N. Budh, C. Hultling, et al., Neuropathic pain after traumatic spinal cord injury relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord, 2004, 42: 665-673.

[4]

F. M Perkins, H. Kehlet, Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology, 2000, 93: 1123-1133.

[5]

N. Harden, M. Cohen, Unmet needs in the management of neuropathic pain. The Journal of Pain and Symptom Management, 2003, 25: S12-S17.

[6]

G.J. Bennett, Y. K Xie, A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Journal of Pain, 1988, 33: 87-107.

[7]

Y. Jin, J. Sato, M. Yamazaki, et al., Changes in cardiovascular parameters and plasma norepinephrine level in rats after chronic constriction injury on the sciatic nerve. Pain, 2008, 135: 221-231.

[8]

T. Kitazono, R.C. Padgett, M.L. Armstrong, et al., Evidence that angiotensin Ⅱ is present in human monocytes. Circulation, 1995, 91: 1129-1134.

[9]

D.D. Potter, C.G. Sobey, P.K. Tompkins, et al., Evidence that macrophages in atherosclerotic lesions contain angiotensin Ⅱ. Circulation, 1998, 98: 800-807.

[10]

K.A. Nahmod, M.E. Vermeulen, S.R. Salamone, et al., Control of dendritic cell differentiation by angiotensin Ⅱ. FASEB Journal, 2003, 17: 491-493.

[11]

Y.N. Nabah, T. Mateo, R. Estelles, et al., Angiotensin Ⅱ induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation, 2004, 110: 3581-3586.

[12]

E. Fusayasu, H. Kowa, T. Takeshima, et al., Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain, 2007, 128: 209-214.

[13]

H. Ba'albaki, A.M. Rapoport, Mast cells activate the renin angiotensin system and contribute to migraine: a hypothesis. Headache, 2008, 48: 1499-1505.

[14]

S. Takai, K. Song, T. Tanaka, et al., Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin Ⅱ receptor antagonist in mice. Life Sciences, 1996, 59: PL331-PL336.

[15]

A. Cerulli, F.H. Frech, and D.G. Smith, Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis. Clinical Pharmacology & Therapeutics, 2005, 27: 951-959.

[16]

L.J. Brookman, I.S. Benjamin, and P.E. Rolan, Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology & Therapeutics, 1997, 62(3): 272-278.

[17]

G.L. Amidon, R. Lobenberg, Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50: 3-12.

[18]

C. Brunella, D.M. Clelia, and I.A. Maria, Improvementof solubility and stability of valsartan by hydroxypropyl-beta-cycledextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 54: 289-294.

[19]

K. Manjunath, J.S. Reddy, and V. Venkateswarlu, Solid lipid nanoparticles as drug delivery systems. Clinical and Experimental Pharmacology and Physiology, 2005, 27(2): 1-20.

[20]

K. Mader, W. Mehnert. Solid lipid nanoparticles production, characterization and applications. Advanced Drug Delivery Reviews, 2001, 47: 165-196.

[21]

F.Q. Hu, S.P. Jiang, Y.Z. Du, et al., Preparation and characterization of monostearin nanostructured lipid carriers. International Journal of Pharmaceutics, 2006, 314: 83-89.

[22]

K.K. Sawant, B. Parmar, K.C. Petkar, et al., Valsartan loaded solid lipid nanoparticles: Development, characterization, and in vitro and ex vivo evaluation. International Journal of Pharmaceutical Sciences and Nanotechnology, 2011, 4(3): 1483-1490.

[23]
S. D'Souza. A review of in vitro drug release test methods for nano-sized dosage forms. Advances in Pharmaceutics, 2014: ID 304757.
[24]

S. S Sharma, P.R. Joshi, N. Geeta, et al., SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: An insight into its mechanism for neuroprotection. Nanomedicine: Nanotechnology, Biology and Medicine, 2013, 9: 776-785.

[25]

S. Kambiz, J.W. van Neck, S.G. Cosgun, et al., An early diagnostic tool for diabetic peripheral neuropathy in rats. PloS One, 2018, 10(5): e0126892.

[26]

S.D. Nandedkar, P.E. Barkhaus, Contribution of reference electrode to the compound muscle action potential. Muscle & Nerve, 2007, 36(1): 87-92.

[27]

G. Negi, A. Kumar, R.K. Kaundal, et al., Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology, 2009, 58: 585-592.

[28]

A. Fox, C. Eastwood, C. Gentry, et al., Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain, 1999, 81(3): 307-316.

[29]

M.J. Masarudin, S.M. Cutts, B.J. Evison, et al., Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: Application to the passive encapsulation of [14C]-doxorubicin. Nanotechnology Science and Applications, 2015, 8: 67.

[30]

G. Dikmen, G. Guney, and L. Genc, Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells. Recent Patents on Anti-Cancer Drug Discovery, 2015, 10(2): 224-232.

[31]

A. Mishra, S.S. Imam, M. Aqil, et al., Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation. Drug Delivery, 2016, 23(4): 1486-1494.

[32]

S.L. Bao, J. Pan, H.X. Sun, et al., Valsartan improves cardiac function in mice with diabetes mellitus by CaMKII/AngII. European Review for Medical and Pharmacological Sciences, 2018, 22(16): 5327-5334.

Nano Biomedicine and Engineering
Pages 306-312
Cite this article:
Radhakrishnan A, Venkatachalam S, Paruchuri B. Design and Development of Valsartan-Loaded Solid Lipid Nanoparticles for the Enhanced Protection from Diabetic Neuropathy. Nano Biomedicine and Engineering, 2019, 11(3): 306-312. https://doi.org/10.5101/nbe.v11i3.p306-312

623

Views

29

Downloads

2

Crossref

2

Scopus

Altmetrics

Received: 20 January 2019
Accepted: 18 September 2019
Published: 20 September 2019
© Arun Radhakrishnan, Senthil Venkatachalam, and Bhavani Paruchuri.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return